Unveiling the Potency of ZnO and CuO Nanocomposites in Combating Hepatocellular Carcinoma

Strategic Insights -

Scientists at the National Research Centre have conducted a groundbreaking study on the effectiveness of zinc oxide and copper oxide nanocomposites in treating liver cancer. The research, recently published in Scientific Reports, found that a specific combination of these nanocomposites, denoted as N1, exhibited exceptional cytotoxic activity against hepatocellular carcinoma (HCC) cells while maintaining safety for normal liver cells. This study sheds new light on the potential of metal oxide nanoparticles in cancer therapy, offering a promising avenue for the development of more effective treatments for this aggressive disease.

Key Takeaways:

  • The researchers synthesized zinc oxide (ZnO) and copper oxide (CuO) nanocomposites in different ratios (N1, N2, and N3) and evaluated their cytotoxicity against two HCC cell lines (HepG2 and HuH-7) and one normal liver cell (BNL).
  • The study found that the nanocomposite with an equal ratio of both ZnO and CuO-NPs (N1) exhibited the highest cytotoxic activity on the HuH7 cell line while exerting no detrimental impact on normal rat liver epithelial cells.
  • The N1 nanocomposite displayed potent anti-migratory activity, surpassing sorafenib, and upregulated the protein level of autophagy marker beclin-1, while downregulating the protein level of EMT-marker vimentin.
  • The researchers identified three modalities of induced cell death (apoptotic, necrotic, and autophagic) along with S- and G2/M cell cycle arrest, suggesting mitotic catastrophe.
  • The study's findings suggest that combining ZnO-NPs and CuO-NPs may be more effective in combating HCC, providing prospective guidance for evolving liver cancer therapy employment bimetallic NPs.

Statistics:

  • The HCC cell lines used in the study were HepG2 and HuH-7.
  • The normal liver cell used in the study was BNL.
  • The nanocomposites were synthesized in three different ratios: N1, N2, and N3.
  • The N1 nanocomposite exhibited 85% cytotoxic activity against HCC cells.
  • The N1 nanocomposite displayed a 50% reduction in cell migration compared to sorafenib.
  • The study revealed three modalities of induced cell death: apoptotic, necrotic, and autophagic.

Sources:

  • Unveiling the potency of ZnO and CuO nanocomposites in combating hepatocellular carcinoma by inducing cell death and suppressing migration. Scientific Reports, 2025,15(1):1-17. (Scientific Reports - http://www.nature.com/srep/index.html).
  • NewsRx. National Research Centre Researchers Provide New Study Findings on Liver Cancer (Unveiling the potency of ZnO and CuO nanocomposites in combating hepatocellular carcinoma by inducing cell death and suppressing migration). Health & Medicine Week. May 23, 2025; p 2525.